全球癌症診斷市場-2023年至2028年預測
市場調查報告書
商品編碼
1295345

全球癌症診斷市場-2023年至2028年預測

Global Cancer Diagnostics Market - Forecasts from 2023 to 2028

出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 130 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2021 年癌症診斷市場價值為 124.1 億美元,預計將以 18.40% 的複合年增長率增長,到 2028 年將達到 404.69 億美元。

癌症診斷市場是指涉及用於診斷癌症的測試和技術的開發、生產和商業化的醫療行業領域。 這包括廣泛的診斷工具,例如成像測試(例如 X 射線、CT 掃描、MRI 掃描)、血液測試、活組織檢查和分子診斷測試(例如基因測試和腫瘤標誌物測試)。 癌症診斷市場是醫療保健行業的一個重要領域,因為早期準確的癌症診斷對於有效治療和改善患者預後至關重要。 癌症診斷市場的主要參與者包括 BioMerieux SA、F. Hoffmann-La Roche Ltd、Sienna Cancer Diagnostics、Insight Medical Genetics 等。 這些公司大力投資研發,開發新技術和解決方案,以滿足不斷增長的需求。

癌症發病率的上升是推動癌症診斷需求的重要因素。

癌症是全世界死亡的主要原因,其發病率正在以驚人的速度增長。 據世界衛生組織(WHO)稱,2020年,將有約1930萬新發癌症病例和1000萬癌症相關死亡病例。 此外,預計未來20年新發癌症病例數將增加47%,到2040年新發病例數將超過2800萬。 隨著癌症患者數量的不斷增加,人們越來越需要更有效和高效的診斷工具來早期檢測和診斷癌症。 癌症的早期發現對於改善患者的預後至關重要,因為它可以進行早期干預和早期治療,並且可以增加獲得良好結果的可能性。

世界各國政府越來越認識到癌症診斷技術的潛力。

例如,2021 年,美國 FDA 授予 Grail Inc. 用於早期癌症檢測的液體活檢測試突破性器械稱號。 這一稱號旨在促進新技術的開發和審查,這些新技術顯示出為危及生命和不可逆轉的衰弱疾病提供更有效的診斷、治療和預防的潛力。

市場趨勢:

  • 2021 年,bioMerieux SA 宣布收購 Canadian Bioinformatics Solutions (BSI),這是一家蛋白質組學和基因組學分析軟件解決方案專家。 通過此次收購,生物梅裡埃增強了其在下一代基於測序的癌症診斷方面的能力。
  • 2021 年 6 月,Grail 推出了 Galleri,這是一種血液測試,利用血液中的腫瘤 DNA 片段來識別約 50 種癌症。 該檢測在美國可憑處方獲得,旨在篩查 50 歲以上癌症風險較高的個人。 Grail 的推出使 Grail 成為針對多種癌症開發基於血液的篩查測試的領導者之一,與 Guardant Health、FreeNorm 和 Thrive Early Inspection 競爭。
  • 2021 年,領先的診斷解決方案提供商 Thermo Fisher Scientific 宣布推出新的 Oncomine Dx Target Test。 使用這種下一代測序儀進行的癌症診斷測試可以檢測各種癌症的基因突變。 該測試非常準確,可以檢測多個基因的突變,為醫生做出治療決策提供有價值的信息。

從診斷程序來看,癌症診斷市場主要包括臨床測試、影像學測試和活檢。 預計臨床測試領域將在預測期內佔據重要的市場份額。 臨床檢測部分進一步分為血液檢測、尿液檢測和基因檢測。

乳腺癌領域預計將佔據重要份額,因為它是全世界女性最常見的癌症之一。

近年來,乳腺癌診斷工具和技術的開發投入快速增加,乳腺癌診斷藥物市場有望進一步增長。 根據國防部乳腺癌研究計劃報告(2021 年 10 月),截至 2020 年,女性乳腺癌是全球最常診斷的癌症,估計有 230 萬新發病例。我在這裡。 到 2021 年,僅在美國就有大約 281,550 名女性和 2,650 名男性被診斷出患有浸潤性乳腺癌。 隨著乳腺癌患者數量的增加,對能夠早期發現和及時治療的癌症診斷技術和產品的需求不斷增長。

根據全球癌症觀測站(GCO)的數據,人口最多的大陸亞洲將在2020年新增癌症病例數最高,約為950萬例。 與此同時,在北美和歐洲,同年新增癌症患者人數超過650萬。 菸酒消費量增加、久坐的生活方式、不健康的飲食習慣以及遺傳因素導緻美國癌症患者數量大幅增加。 例如,根據美國癌症協會提供的數據,美國新診斷癌症病例為190萬例,而2020年報告的新發病例為180萬例,相比之下增加了5.6%。 該消息來源還估計,2021 年癌症死亡人數估計為 6,085,570 人,增加了 2,050 人。 癌症診斷病例和死亡率的增加將推動對癌症早期發現的診斷和篩查活動的需求,從而推動美國癌症診斷市場的增長。

內容

第 1 章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場細分
  • 貨幣
  • 先決條件
  • 基準年和預測年的時間表

第 2 章研究方法

  • 研究設計
  • 調查數據
  • 驗證

第 3 章執行摘要

  • 主要發現

第 4 章市場動態

  • 市場促進因素
  • 市場抑制因素
  • 波特五力分析
  • 行業價值鏈分析

第 5 章全球癌症診斷藥物市場:按診斷治療劃分

  • 簡介
  • 臨床檢查
  • 影像檢查治療
  • 活檢

第 6 章癌症診斷藥物的全球市場:按應用劃分

  • 簡介
  • 肺癌
  • 乳腺癌
  • 結直腸癌
  • 皮膚癌
  • 胃癌
  • 其他

第 7 章癌症診斷藥物的全球市場:按最終用戶劃分

  • 簡介
  • 醫院和診所
  • 診斷中心

第 8 章全球癌症診斷藥物市場:按地區劃分

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 以色列
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 台灣
    • 印度尼西亞
    • 日本
    • 其他

第 9 章競爭格局與分析

  • 主要公司及戰略分析
  • 新興公司和市場盈利能力
  • 合併、收購、協議和合作
  • 供應商競爭力矩陣

第 10 章公司簡介

  • bioMerieux SA
  • F. Hoffmann-La Roche Ltd
  • Sienna Cancer Diagnostics
  • Insight Medical Genetics
  • MetaCell
  • Breath Diagnostics, Inc
  • Arquer Diagnostics Ltd
  • Metabiomics
  • Castle Biosciences, Inc.
  • Exact Sciences Corporation
簡介目錄
Product Code: KSI061611698

The cancer diagnostics market was valued at US$12.410 billion in 2021 and is expected to grow at a CAGR of 18.40% to be valued at US$40.469 billion by 2028.

The cancer diagnostics market refers to the healthcare industry segment that deals with the development, production, and commercialization of tests and technologies used to diagnose cancer. This includes a wide range of diagnostic tools, including imaging tests (such as X-rays, CT scans, and MRI scans), blood tests, biopsies, and molecular diagnostic tests (such as genetic and tumor marker tests). The cancer diagnostics market is an important segment of the healthcare industry, as early and accurate cancer diagnosis is crucial for effective treatment and improved patient outcomes. Key players in the cancer diagnostics market include bioMerieux SA, F. Hoffmann-La Roche Ltd, Sienna Cancer Diagnostics, and Insight Medical Genetics. These companies are investing heavily in research and development to develop new technologies and solutions to meet the growing demand.

The rising incidences of cancer is a significant factor driving the demand for cancer diagnostics.

Cancer is a leading cause of death worldwide, and the incidence of the disease is increasing alarmingly. According to the World Health Organization (WHO), there were approximately 19.3 million new cancer cases and 10 million cancer-related deaths in 2020. Furthermore, it is estimated that the number of new cancer cases will increase by 47% in the next two decades, with over 28 million new cases expected by 2040. As the number of cancer cases continues to rise, there is a growing need for more effective and efficient diagnostic tools to detect and diagnose the disease at an early stage. Early cancer detection is crucial for improving patient outcomes, as it enables earlier intervention and treatment, which can increase the chances of a positive outcome.

Governments around the world are increasingly recognizing the potential of cancer diagnostics technologies.

For instance, in 2021, the US FDA granted Breakthrough Device designation to Grail Inc.'s liquid biopsy test for early cancer detection. This designation is intended to expedite the development and review of new technologies that demonstrate the potential to provide more effective diagnosis, treatment, or prevention of life-threatening or irreversibly debilitating diseases.

Market Developments:

  • In 2021, bioMerieux SA announced the acquisition of Bioinformatics Solutions Inc. (BSI), a Canadian company specializing in software solutions for proteomics and genomics analysis. This acquisition will enhance bioMerieux's capabilities in next-generation sequencing-based cancer diagnostics.
  • In June 2021, Grail introduced its Galleri blood test, which uses fragments of tumor DNA in the bloodstream to identify almost 50 different cancers. The test is available in the United States with a prescription and is intended for screening individuals over 50 who have an increased risk of cancer. The launch established Grail as one of the leaders in developing blood-based screening tests for various types of cancer, competing with Guardant Health, Freenome, and Thrive Earlier Detection.
  • In 2021, Thermo Fisher Scientific, a leading provider of diagnostic solutions, announced the launch of its new Oncomine Dx Target Test. This next-generation sequencing-based cancer diagnostic test can detect genetic mutations in various types of cancer. The test is highly accurate and can detect mutations in multiple genes, providing physicians with valuable information to guide treatment decisions.

By diagnostic procedures, the global cancer diagnostics market mainly comprises laboratory tests, imaging procedures, and biopsy. During the forecast period, the laboratory test segment is expected to hold a considerable market share. The laboratory test diagnostic procedures segment is further categorized into blood, urine, and genetic tests.

The breast cancer segment is expected to hold a sizeable share as one of the most common types of cancer in women worldwide.

In recent years, there has been a surge in investment in the development of diagnostic tools and technologies for breast cancer, which is expected to fuel further growth in the breast cancer diagnostics market. According to a report by the Department of Defense Breast Cancer Research Program, October 2021, as of 2020, female breast cancer has become the most diagnosed cancer globally, with an estimated 2.3 million new cases. In 2021, about 281,550 women and 2,650 males will be diagnosed with invasive breast cancer in the United States alone. As the number of breast cancer patients grows, there is a heightened demand for cancer diagnostic technologies and products to ensure early detection and prompt treatment.

By geography, the global cancer diagnostics market has been analyzed into North America, South America, Europe, Asia Pacific, and Middle East and Africa.According to data from the Global Cancer Observatory (GCO), Asia, the most populated continent, accounted for the highest number of new cancer cases in 2020, with almost 9.5 million new cases. Meanwhile, North America and Europe combined for more than 6.5 million new cancer cases in the same year. The number of cancer cases has shown significant growth in the US owing to growing alcohol & tobacco consumption, sedentary lifestyle, unhealthy eating habits, and genetic factors. For instance, according to the data provided by the American Cancer of Society, the estimated number of new cancer-diagnosed cases in the US stood at 1.9 million which represented a 5.6% increase in newly diagnosed cases in comparison to 1.8 million new cases reported in 2020. Also, as per the same source, the estimated number of cancer deaths in 2021 stood at 6,08,570, signifying an increase of 2,050 in the number of deaths. Such an increase in cancer-diagnosed cases and the death rate will propel the demand for diagnostics and screening activities for early cancer detection, thereby boosting the market growth of cancer diagnostics in the United States.

Market Segmentation:

BY DIAGNOSTIC PROCEDURES

  • Laboratory Tests
  • Imaging Procedures
  • Biopsy

BY APPLICATION

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Skin Cancer
  • Stomach Cancer
  • Others

BY END-USERS

  • Hospitals and Clinics
  • Diagnostic Centers

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • South Korea
  • Taiwan
  • Indonesia
  • Japan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Data
  • 2.3. Validation

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. GLOBAL CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC PROCEDURES

  • 5.1. Introduction
  • 5.2. Laboratory Tests
  • 5.3. Imaging Procedures
  • 5.4. Biopsy

6. GLOBAL CANCER DIAGNOSTICS MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Lung Cancer
  • 6.3. Breast Cancer
  • 6.4. Colorectal Cancer
  • 6.5. Skin Cancer
  • 6.6. Stomach Cancer
  • 6.7. Others

7. GLOBAL CANCER DIAGNOSTICS MARKET, BY END-USERS

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
  • 7.3. Diagnostic Centers

8. GLOBAL CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. South Korea
    • 8.6.4. Taiwan
    • 8.6.5. Indonesia
    • 8.6.6. Japan
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. bioMerieux SA
  • 10.2. F. Hoffmann-La Roche Ltd
  • 10.3. Sienna Cancer Diagnostics
  • 10.4. Insight Medical Genetics
  • 10.5. MetaCell
  • 10.6. Breath Diagnostics, Inc
  • 10.7. Arquer Diagnostics Ltd
  • 10.8. Metabiomics
  • 10.9. Castle Biosciences, Inc.
  • 10.10. Exact Sciences Corporation